Phase I-II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities

Melanoma Research

Volumn 13, Issue 3, 2003, Pages 293-297

  Rossi, C R ^a   Lejeune, F J ^b   Pontes, L ^c   Foletto, M ^a   De Salvo, G L ^d   Pilati, P L ^a   Mocellin, S ^a   Ribeiro, M ^c   Lopes, M ^c   Lise, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Ctr Pluridisciplinaire d'Oncol   (Switzerland)

^c PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^d Uff Epidemiologia Clin COR P   (Italy)

Author keywords

Advanced melanoma; Dacarbazine; Fotemustine; Isolation limb perfusion

Indexed keywords

DACARBAZINE; FOTEMUSTINE;

ADULT; ADVANCED CANCER; AGED; ARTERY OCCLUSION; ARTICLE; BULLOUS SKIN DISEASE; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; LIMB PERFUSION; LYMPHEDEMA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; NECROSIS; PARALYSIS; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NERVE; TREATMENT OUTCOME; VEIN THROMBOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DACARBAZINE; EXTREMITIES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 12444250678     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200306000-00011     Document Type: Article

References (18)

1. Creech O, Krementz E, Ryan R. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1956; 148:616-632.
2. Rossi CR, Foletto M, Vecchiato A, Alessio S, Menin N, Lise M. Management of cutaneous melanoma MO: state of the art and trends. Eur J Cancer 1997; 33:2302-2312.
3. Fraker DL. Hyperthermic regional perfusion for melanoma and sarcoma of the limbs. Curr Probl Surg 1999; 36:641-907.
4. Rossi CR, Foletto M, Pilati P, Mocellin S, Lise M. Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol 2002; 29:400-409.
5. Lienard D, Eggermont AM, Koops HS, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9:491-502.
6. Pontes L, Lopes M, Ribeiro M, Santos JG, Azevedo MC. Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma. Melanoma Res 1997; 7:417-419.
7. Walker MC, Masters JR, Margison GP. O6-alkylguanine-DNA-alkyltransferase activity and nitrosourea sensitivity in human cancer cell lines. Br J Cancer 1992; 66:840-843.
8. Gerson SL, Willson JK. O6-alkylguanine-DNA alkyltransferase. A target for the modulation of drug resistance. Hematol Oncol Clin North Am 1995; 9:431-450.
9. Lee SM, Thatcher N, Margison GP. O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res 1991; 51:619-623.
10. Lee SM, Margison GP, Woodcock AA, Thatcher N. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer 1993; 67:1356-1360.
11. Gerard B, Aamdal S, Lee SM, et al. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents-dacarbazine and fotemustine-in patients with melanoma. Eur J Cancer 1993; 5:711-719.
12. Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18:905-910.
13. McBride CM. Sarcomas of the limbs. Results of adjuvant chemotherapy using isolation perfusion. Arch Surg 1974; 109:304-308.
14. Stehlin JS Jr. Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet 1969; 129:305-308.
15. Vrouenraets BC, Klaase JM, Kroon BB, van Geel BN, Eggermont AM, Franklin HR. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg 1995; 130:43-47.
16. D'Incalci M, Citti L, Taverna P, Catapano CV. Importance of the DNA repair enzyme O6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev 1966; 15:279-292.
17. Wiestler O, Kleihues P, Pegg AE. O6-alkylguanine-DNA alkyltransferase activity in human brain and brain tumors. Carcinogenesis 1984; 5:121-124.
18. Aamdal S, Avril M, Grob J. A phase III randomized trial of fotemustine versus dacarbazine in patients with disseminated malignant melanoma with or without brain metastases. ASCO Orlando (FL) 2002; 341a.